Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
- - INCLUSION CRITERIA: 1. Patients 18 years of age and older are eligible. 2. Patients must have a performance status of ECOG 0, 1, 2, or 3 for admission to this protocol. 3. Patients with malignancy are eligible. 4. Patients requiring a surgical procedure for any medical indication can be included on study. 5. Patients requiring biopsy or any procedure for any medical indication can be included on study. 6. Patients not requiring biopsy for a medical indication can be included on the study solely for the purpose of obtaining research samples, including blood, pleural fluid, or peritoneal fluid, or biopsy samples, providing the biopsy or aspiration procedure is of minimal risk, i.e. fine needle aspirate, bone marrow aspirate, or excisional biopsy. No radiology tests will be used in the procedure to collect a sample that would not be otherwise used for an appropriate medical indication. 7. Normal volunteers 18 years of age and older are eligible to enroll. Normal volunteers must be willing to sign informed consent and must be willing to provide samples to be used for research. EXCLUSION CRITERIA: 1. Pregnant individuals will not be eligible due to potential risks to the fetus associated with radiologic procedures required for biopsy. 2. Children will not be eligible because of potential risks from complications due to procedures involved in obtaining the biopsies. 3. Normal volunteers with a history of a clotting disorder may not enroll.
Background: Ongoing research in the Experimental and Molecular Therapeutics Sections, NCI, requires the availability of blood, serum, tumor, hair follicle and tissue samples from patients with cancer. Resistance is the underlying cause of treatment failure, and may present as acquired or intrinsic drug resistance. Patients with cancer frequently present with chemotherapy-responsive disease, and undergo tumor response, only to eventually experience relapse, at which time the tumor may be refractory to further treatment. This is termed acquired drug resistance; while intrinsic resistance implies a cancer that is refractory from the outset. Diverse mechanisms of drug resistance have been described and are often dependent upon the particular drug under study. Objectives: To obtain blood, serum, tumor, hair follicle or normal tissue samples that would allow development of assays for use in subsequent clinical trials Eligibility: Patients with a prior diagnosis of malignancy, with advanced or refractory cancer will be evaluated in the Medical Oncology Clinic, NCI. Blood samples or hair follicle samples may be collected at the initial visit, and at follow up visits. Tumor samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal fluid, or by excisional biopsy, providing the tumor is accessible with a minimal risk to the patient. Patients may be on, or in the process of being evaluated for a research protocol. Patients may receive treatment on the standard care protocol. Normal volunteers may enroll in the study for collection of blood or hair follicle samples. Design: Acquired samples will be recorded in the computerized data bank currently existing in the Molecular Therapeutics Section. No germline testing will be performed on any of the samples collected. Tests will be pilot studies relating to the Section s work on the biology of drug resistance and cell survival in cancer. If any research tests are considered to be themselves of more than minimal risk to the patient, separate permission will be requested from the IRB to perform that test, and a new consent will be obtained. Examples of the types of studies to be performed with biopsies will be drug resistance gene expression assays, with the goal of demonstrating the utility of the assay in patient samples. Evaluation of methods to detect drug resistance proteins and genes will be explored, including Northern blot, immunoblot, polymerase chain reaction assay, and RNA in situ hybridization. With whole blood, we may evaluate the presence of dye transport in an ex vivo assay, for example, using inhibitors of ABCG2. Evidence of drug accumulation or DNA damage may be sought in patient mononuclear cells or in hair follicle samples.
Trial Phase Phase NA
Trial Type Not provided by clinicaltrials.gov
National Cancer Institute
William Douglas Figg
- Primary ID 000078
- Secondary IDs NCI-2018-02161, 00-C-0078, NCI-2013-02019
- Clinicaltrials.gov ID NCT00026663